Department of Pediatrics and.
Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
J Clin Invest. 2020 Jun 1;130(6):2816-2819. doi: 10.1172/JCI137051.
Programmed cell death protein 1 (PD-1) has become one of the most investigated targets for cancer immunotherapy. Most research has centered on inhibiting PD-1 on T cells, but there is increased interest in understanding the role of PD-1 on NK cells. While the expression of PD-1 on NK cells has been controversial, with papers publishing contradictory results in multiple models, there is increased clinical interest in NK and PD-1 immunotherapy. In this issue of the JCI, Judge et al. comprehensively explore the lack of PD-1 expression on murine, canine, and human NK cells and the clinical implication of these findings.
程序性细胞死亡蛋白 1（PD-1）已成为癌症免疫疗法研究最多的靶点之一。大多数研究都集中在抑制 T 细胞上的 PD-1，但人们越来越关注了解 PD-1 在 NK 细胞上的作用。虽然 NK 细胞上 PD-1 的表达一直存在争议，多篇论文在多个模型中发表了相互矛盾的结果，但 NK 和 PD-1 免疫疗法的临床兴趣正在增加。在本期 JCI 中，Judge 等人全面探讨了 PD-1 在鼠、犬和人 NK 细胞上表达的缺乏及其临床意义。
